The Scientist

» retraction watch, disease/medicine and culture

Most Recent

image: Universal Flu Vaccines Charge Ahead

Universal Flu Vaccines Charge Ahead

By | January 14, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

0 Comments

image: It’s Elementary

It’s Elementary

By | January 10, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

3 Comments

image: Opinion: Diagnostics Needed

Opinion: Diagnostics Needed

By | January 10, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

2 Comments

image: Repoopulation Remedy

Repoopulation Remedy

By | January 9, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

1 Comment

image: The Sodium Cycle

The Sodium Cycle

By | January 8, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

3 Comments

image: Lab Safety in the Spotlight

Lab Safety in the Spotlight

By | January 4, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

1 Comment

image: Cancer Biomarker Studies Retracted

Cancer Biomarker Studies Retracted

By | January 3, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

0 Comments

image: Game On

Game On

By | January 3, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

0 Comments

image: Expensive Retraction

Expensive Retraction

By | January 2, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

2 Comments

image: A Dime a Dozen

A Dime a Dozen

By | January 1, 2013

Researchers and biotech companies are bringing a universal flu vaccine closer to reality.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech